Immuno-Oncology Recapitulates Ontogeny: Modern Cell and Gene Therapy for Cancer

Pittsburgh, Pennsylvania, a team of researchers from the University of Pittsburgh Medical Center has made a groundbreaking discovery in the field of cancer gene therapy. According to the study, immuno-oncology has evolved significantly over the past century, with the introduction of immune checkpoint blockade (ICB) in the last 15 years revolutionizing cancer treatment. The researchers have identified new applications for cell and gene therapies, including armed adenovirus and oncolytic herpesvirus, which have shown remarkable clinical and commercial success. This study highlights the co-evolutionary interactions between the epithelium and the immune system, providing a better understanding of the molecular biology of cancer and the physiology of immunobiology.

Key Takeaways:

• The researchers have identified over a century of development in immuno-oncology, from the original insights of Virchow in 1863 to the current central pillar of cancer treatment.
• Immune checkpoint blockade (ICB) has been a game-changer in cancer treatment, with remarkable clinical and commercial success over the last 15 years.
• The study highlights the importance of foundational understanding of immune system learning and evolvability in facilitating better co-evolutionary interactions between the epithelium and the immune system.
• The researchers have identified new applications for cell and gene therapies, including armed adenovirus and oncolytic herpesvirus, which have shown promising results in cancer treatment.
• The study provides examples of next-generation cell and gene therapies that intercept cancer development, including breast, colon, prostate, pancreas, and lung cancer.
• The researchers stress the importance of understanding the molecular biology of cancer and the physiology of immunobiology in developing effective cancer treatments.
• The study is a significant contribution to the field of cancer gene therapy, providing new insights and approaches for the treatment of cancer patients.

Statistics:

• 15 years - the duration of Immune checkpoint blockade (ICB) revolutionizing cancer treatment.
• 100+ years - the history of immuno-oncology development.
• 5 types of cancer - breast, colon, prostate, pancreas, and lung cancer - highlighted by the researchers as examples of next-generation cell and gene therapies that intercept cancer development.
• 4 types of cell and gene therapies - armed adenovirus, oncolytic herpesvirus, chimeric antigen receptor T (CAR-T) cells, and tumor-infiltrating lymphocytes (TILs) - identified by the researchers as promising approaches for cancer treatment.
• 2025 - the year in which the research was published in the journal Molecular Therapy.

Sources:

• NewsRx. Data on Cancer Gene Therapy Detailed by Researchers at University of Pittsburgh Medical Center (Immuno-oncology Recapitulates Ontogeny: Modern Cell and Gene Therapy for Cancer). Cancer Weekly. July 22, 2025; p 26.
• Immuno-oncology Recapitulates Ontogeny: Modern Cell and Gene Therapy for Cancer. Molecular Therapy, 2025;33(5):2229-2237.